CSL gets a new CEO after Paul Perreault’s successful 9-year tenure ends
Nick Sundich, December 13, 2022
One of the most prominent hot seats among ASX companies is CSL CEO and there’s a change coming next year. After a 9-year tenure, Paul Perreault is retiring, and Chief Operating Officer Paul McKenzie will succeed him.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Who is the new CSL CEO?
Paul McKenzie is currently CSL’s COO and has only been there since 2019. But he comes with over 3 decades of leadership experience in the global biotech sector. Most notably, he helped grow the Seqirus, Plasma and Vifor businesses amidst the global pandemic.
McKenzie will take over as CEO on 6 March next year. He will be paid US$1.75m per annum as a base salary, with the potential for bonuses.
Will the next decade be as spectacular as the first?
Shareholders should take comfort in having an internal candidate as CEO. No doubt McKenzie will be able to shift into the hot seat easier than an external candidate.
Yet, we expect a poor share price response in the next few days, because investors never like it when a long-term CEO stands down, especially one with such a solid record as Paul Perreault.
ASX:CSL share price growth during Paul Perrault’s tenure as CEO (Graph: TradingView)
At the same time, CSL is far from a microcap that is solely reliant on its CEO to run the company. So, longer term we expect CSL to continue its solid track record of growth in the years ahead.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?
The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…